The nation of Zimbabwe has rejected a significant American healthcare agreement worth 367 million US dollars (£272m) over five years because of Washington's insistence on sensitive information.
This rejection was revealed after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
A government spokesperson later clarified that the US was demanding access to biological samples for research and commercial gain while was not willing to share the benefits from future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for more negotiations to secure a agreement suitable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection follows a similar situation in neighbouring Kenya, where a court halted a similar health funding agreement following legal challenges were raised about the safety of Kenyans' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump stated its expenditure was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
As per reports, 16 African countries have so far agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation would have delivered immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment through US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," his statement read.
"In essence, our nation would supply the basic resources for medical research with no assurance that the end products would be available to our people should a new disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining systems already established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage future pandemics.
"This framework is designed to ensure that when a nation provides its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to develop them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration could be structured in a manner that respects the sovereignty and dignity of each country."
Medical Community Response
A leading public health body expressed it understood the government's concerns, but urged that negotiations should continue given that much of the nation's Aids initiatives depended on foreign aid.
"In cases where specific concerns exist, such as those relating to data governance or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," it said.
The situation underscores the complex tensions between accepting vital foreign assistance and protecting national sovereignty in an ever more data-driven world.